Isis cancer, autoimmune/inflammation, infectious diseases news

ISIS reduced its headcount by 9%, which included personnel involved in commercializing and manufacturing its Affinitak antisense compound to treat non-small cell lung cancer (NSCLC). Last month, ISIS ...